The stock rose 6% after Gland Pharma reported strong Q1 FY26 results. Revenue increased 7% YoY and 6% QoQ to ₹1,506 crore, while net profit surged 49% YoY to ₹215 crore. EBITDA grew 39% YoY to ₹368 crore, with margin expanding to 24.4%, indicating improved operational efficiency and profitability.